Companies

Request More Information

Last:
Change: Change(%):
Volume: Open:
High: Low:
52Wk High: 52Wk Low:

Experts Commenting on This Company

 

Visit Company Website

View Company News


Omeros Corp.

TICKER: OMER:NASDAQ

Omeros Corp. is a clinical-stage biopharmaceutical company discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system. Lead drug product Omidria (OMS302) for lens replacement surgery is under review for marketing approval by both FDA and the European Medicines Agency, with U.S. commercial launch planned for H2/14. Omeros' five other clinical programs are focused on schizophrenia; Huntington's disease and cognitive impairment; addictive and compulsive disorders; complement-related diseases; and preventing problems associated with surgical procedures. Omeros' proprietary G protein-coupled receptor (GPCR) platform is making available many new GPCR drug targets and corresponding compounds to the pharmaceutical industry for drug development.


The information provided below is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.

Expert Comments:

Jason Kolbert, Maxim Group (10/22/14) "Omeros Corp. self-imposed a temporary suspension of OMS824 Huntington's disease trial. . .what does this mean? Likely not much, but we are confident that the right call is being made by Omeros to temporarily suspend the current Phase 2 trial to be cautious. Omeros has had communications with the FDA and it agreed that Omeros should sort out the preclinical data."

George Zavoico, MLV & Co (10/22/14) "Yesterday, Omeros Corp. announced enrollment suspension of a Phase 2 trial of OMS824 for he treatment of Huntington's disease due to higher-than-expected free-plasma drug concentrations seein in a parallel non-clinical study in rats. . .we continue to believe OMS824 to be safe. . .and expect the Phase 2 trial to resume after this issue is resolved, we think within a few months. We reiterate our Buy recommendation."

The Life Sciences Report interview with Liana Moussatos (8/21/14) "Omeros Corp.'s drug Omidria (phenylephrine + ketorolac) [was] approved on May 30 for cataract and other intraocular lens replacement surgeries. The company announced the approval on June 2. A lot of fast money sold on the catalyst, but just a few days later Omeros started rising. That's because the longer-term investors had done their homework, had gotten comfortable with the market potential of Omidria, and had started buying the stock. . .

There's more to Omeros than Omidria. The company has quite a pipeline. It has two significant Phase 2 trials that will provide data around the end of this year. One is the company's human monoclonal antibody OMS721 for thrombotic microangiopathies. . .Omeros' other pipeline drug is OMS824, a phosphodiesterase 10 inhibitor for Huntington's disease. . .I think the Phase 2 data from either one of these trials could solidify Omeros. . . More >

Mick Cooper, Edison Investment Research (7/3/14) "The FDA's approval of Omeros Corp.'s Omidria on May 30, 2014, for use during cataract surgery or lens replacement will start the U.S. launch process in late summer/early autumn of 2014. . .anticipation of a good price point at launch and EU approval (with potential for an EU partnering deal) would maintain momentum through 2014. . .importantly, the use of Omidria does not require major changes to operating procedures and there is no other product on the market that combines a mydriatic agent (pupil dilator) and an NSAID for pain relief."

The Life Sciences Report Interview with Jason Kolbert (6/4/14) "I really like following Omeros Corp. It is a specialty pharma coupled with a true biotech company, and is working on a couple of exciting products. Dr. Greg Demopulos, the CEO, is an orthopedic surgeon—he's brilliant.

Omeros has just received approval of Omidria (OMS302; phenylephrine + ketorolac), which was developed for intraocular lens (IOL) replacement. We think Omidria can be reasonably successful. It allows the ophthalmic surgeon to retain both a dilated surgical field as well as reduce the inflammation and pain associated with the surgery. It provides a convenience factor and a better outcome for what tends to be an elective procedure. There is the potential for Omidria to be a couple-hundred-million-dollar product, and to build free cash flow for the company. That would fund the development of Omeros' pipeline. . ." More >

more comments

Jason Kolbert, Maxim Group (6/2/14) "Omeros Corp. announced this morning that OMS302, or Omidria, has been approved. We currently assume OMS302 (intraocular lens replacement surgery) will see a full launch in Q4/14 with some sales beginning in Q3/14. . .we believe global sales could reach north of $300M by 2017 for OMS302."

Jason Kolbert, Maxim Group (5/20/14) "Omeros Corp. recently announced positive data using OMS721, the lead human monoclonal antibody in the company's mannan-binding lectin-associated serine protease-2 program. . .we believe investors should pay close attention to this program in light of the success of Alexion Pharmaceuticals Inc.'s eculizumab (Soliris), which is an anti-C5 monoclonal antibody that is approved by the U.S. Food and Drug Administration and the European Medicines Agency to treat patients with atypical hemolytic uremic syndrome."

Jason Kolbert, Maxim Group (3/11/14) "Omeros Corp. announced positive data using OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 (MASP-2) program. . .the data suggests that OMS721 significantly inhibited complement deposition in the model using serum samples from aHUS patients obtained during the acute phase of disease. . .the potential of the Omeros MASP-2 antibody is significant, in our opinion. MASP-2 is the only protein unique to, and required for, the function of the lectin complement pathway."

The Life Sciences Report Interview with George Zavoico (3/6/14) "Omeros [has] a number of features that I find interesting. First is the near-term approval of a niche product called Omidria, [an] irrigant for use in intraocular lens replacement surgery to reduce inflammation and postoperative pain. . . we think this is a low-cost, high margin and volume product that could generate about $100M in sales in 2016. . .possibly enough to bring Omeros to profitability that same year. . .

The new drug application for Omidria was filed back in the summer, and after that a marketing authorization application was filed with the European Medicines Agency. . .we expect a decision after the standard 10-month review—probably midyear or early Q3/14 for the FDA—with launch sometime before the end of 2014.

Behind Omidria, there's a robust pipeline that the company has advanced into a number of phase 1 and phase 2 trials. These are unique products that could be first-in-class for a number of interesting indications, including some central nervous system and inflammatory indications." More >

The Life Sciences Report Interview with Steve Brozak (2/6/14) "Omeros Corp. has a therapy platform that targets inflammation, whether it be ophthalmic or in joints, specifically in arthroscopic surgery. The idea is to reduce inflammation, thereby reducing postoperative pain and providing for much better outcomes. . .I think it would be easy for Omeros to single-handedly take the market." More >

Jason Kolbert, Maxim Group (2/5/14) "Omeros Corp.'s pipeline progress looks good: The company announced that the FDA granted fast-track designation to OMS824, the company's phosphodiesterase 10 inhibitor, for the treatment of cognitive impairment in patients with Huntington's disease. . .Omeros has conducted successful clinical trials assessing the safety, tolerability, pharmacokinetics and target engagement of a wide range of doses of OMS824 in its phase 1 program. Positive data from the company's OMS824 phase 2a schizophrenia trial were recently announced, and Omeros expects to begin enrolling patients this quarter in its phase 2 trial evaluating OMS824 for Huntington's disease."

fewer comments
Due to permission requirements, not all quotes are shown.

Omeros Corp. Content



Back to Top